Delivering drug to the brain remains a major challenge due to the Blood brain Barrier, which restrict the entry of most systemically administered therapies. Emerging research highlights an alternative route via middle and inner ear, where drug deliver intratympanically may reach the brain through anatomical connection such as the cochlear aqueduct and cerebrospinal fluid pathways.
The inner ear perilymph is know to communicate with cerebrospinal fluid (CSF), enabling diffusion of therapeutic molecules beyond the auditory system and into central nervous system compartments. Preclinical studies have reported higher CSF drug concentrations following intratympanic administration compared to systemic delivery supporting the feasibility of this route for brain targeting.
To enhance transport the round window membrane, researchers are developing nanocarriers and sustain release formulations that improve drug resistance time and permeability within in the ear. Advanced nanoparticles based delivery systems have demonstrated controlled release, and enhanced stability, making them promising tools for ear to brain delivery strategies.
Although still larger in the preclinical research stage, ear to brain delivery may offer future therapeutic potential for neurodegenerative disorders, central auditory pathway disfunctions, and vestibular conditions, while reducing systemic exposure and off target effects.
Could the ear redefine targeted drug delivery for brain disorder?
MBH/PS